|1.||Soriano, Vincent: 7 articles (05/2010 - 05/2003)|
|2.||Barreiro, Pablo: 6 articles (05/2010 - 05/2003)|
|3.||Ribera, Esteban: 5 articles (01/2009 - 01/2005)|
|4.||Lori, Franco: 5 articles (07/2005 - 01/2003)|
|5.||Maida, Ivana: 4 articles (05/2010 - 04/2006)|
|6.||Perronne, Christian: 4 articles (03/2008 - 12/2004)|
|7.||Lisziewicz, Julianna: 4 articles (07/2005 - 01/2003)|
|8.||Haas, David W: 3 articles (06/2014 - 08/2006)|
|9.||Robbins, Gregory K: 3 articles (06/2014 - 08/2006)|
|10.||Ledergerber, Bruno: 3 articles (01/2011 - 09/2005)|
|1.||HIV Infections (HIV Infection)
12/01/1996 - "In conclusion, didanosine monotherapy is an effective treatment of HIV infection. "
02/01/1997 - "Italian multicentre study of didanosine compassionate use in advanced HIV infection. "
05/01/1995 - "Starting in 1988, 72 patients with advanced human immunodeficiency virus (HIV) infection were enrolled in a phase I study of didanosine at the National Cancer Institute. "
08/01/2004 - "A 63-year-old man with human immunodeficiency virus (HIV) infection tolerated several didanosine-containing antiretroviral regimens. "
12/01/2002 - "Didanosine remains a cornerstone nucleoside analogue for the treatment of HIV infection. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
02/01/2003 - "This evaluation includes 394 subjects who participated in Pediatric AIDS Clinical Trials Group (PACTG) Study 152 and received either ZDV alone or in combination with didanosine. "
02/15/2002 - "The contribution of virologic and host factors to CD4 cell depletion associated with human immunodeficiency virus (HIV) type 1 was evaluated in children drawn from a larger efficacy trial of 2 doses of didanosine (ddI) monotherapy (Pediatric AIDS Clinical Trials Group 144). "
03/20/2000 - "Didanosine pharmacokinetics were determined during fasting and fed conditions in HIV-infected children enrolled in the Pediatric AIDS Clinical Trials Group Protocol 144 randomized to receive didanosine at 50 mg/m2 or 150 mg/m2 orally every 12 hr. Pharmacokinetic parameters from patients in the low (n = 39) and high (n = 38) dosing groups were not significantly different, but intersubject variability was substantial. "
11/01/1999 - "Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study."
04/01/1995 - "Among 34 children with AIDS enrolled in a trial with 2'-3' dideoxyinosine (ddI), six (aged 1-6 years) developed liver abnormalities within 2-18 months after institution of ddI. "
11/01/1992 - "Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. "
05/01/1995 - "Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection."
08/01/2007 - "Herein, we developed ex vivo and in vivo models of ATN induced by didanosine (ddI) following infection by the lentivirus, feline immunodeficiency virus (FIV), permitting us to address the working hypothesis that ddI mediates ATN through mitochondrial injury in neurons. "
02/01/2007 - "Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection."
01/01/2007 - "Didanosine enteric-coated capsule: current role in patients with HIV-1 infection."
06/01/1994 - "Clinical and pharmacokinetic data of 61 patients from two trials were analyzed to further evaluate the risk of pancreatitis: 1 (6.3%) of 16 patients who received < 500 mg/day didanosine, 2 (13.3%) of 15 who received 500-750 mg/day, and 15 (50%) of 30 who received > 750 mg/day developed pancreatitis (P < .001). "
06/01/1994 - "Phase I dose-escalating trials of didanosine revealed dose-limiting toxicities, including pancreatitis, and established a total daily dose of 12.5 mg/kg/day as the maximum tolerated dose. "
06/01/2005 - "Rates of pancreatitis in didanosine (ddI) arms seemed to be dose dependent. "
12/15/2004 - "Eleven cases of pancreatitis or symptomatic hyperlactatemia were observed, all in patients receiving didanosine-containing antiretroviral regimens. "
09/01/2003 - "Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. "
|5.||AIDS-Related Complex (ARC)
01/01/1992 - "Neuropathic complaints were frequently observed in a Phase I study of dideoxyinosine (ddI) in 44 patients with AIDS and AIDS-related complex. "
07/01/1990 - "The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles."
05/10/1990 - "We conducted a Phase I open-label trial of 2',3'-dideoxyinosine (ddI) for the treatment of the acquired immunodeficiency syndrome (AIDS) and severe AIDS-related complex. "
06/01/1992 - "Only AZT and 2',3'-dideoxyinosine are available so far for the treatment of AIDS and AIDS-related complex. "
03/01/1992 - "Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex."
|10.||Biological Markers (Surrogate Marker)
|4.||Highly Active Antiretroviral Therapy (HAART)
|5.||Drug Therapy (Chemotherapy)